Abstract: An object of the present invention is to provide a detection agent (diagnostic agent) and a treatment agent targeting c-KIT molecules, which are taken up into tumors early in vivo. As a result of examining a molecular species that specifically binds to c-KIT and a labeling agent and a treatment agent which are coupled to the molecular species, the inventors found that combining an anti-c-KIT antibody fragment and IR700 makes it possible to accumulate the combined product in a tumor for a short period, such as several hours from administration for detecting and treating the tumor. Therefore, the present invention relates to a complex of the antigen-binding fragment of an anti-c-KIT antibody and IR700 and also relates to a detection agent and a treatment agent containing the complex as an active ingredient.

Abstract: A management system for an experimental animal is provided. This management system includes an information identifying unit configured to identify experimental information on the experimental animal to be transported to an experiment site, and a stress value calculating unit configured to calculate a stress value indicating stress to be suffered by the experimental animal during transportation based on the experimental information. The experimental information includes at least a part of a transportation distance for the transportation of the experimental animal, a transportation period for the transportation of the experimental animal, the number of the experimental animals to be transported at a time, an age of the experimental animal, and information on pretreatment given to the experimental animal prior to the transportation.

Abstract: An immunosuppressive agent containing a substance that is selected from anti-CD80 antibodies and anti-PD-L1 antibodies and that promotes binding between PD-L1 and PD-1.

Abstract: A management system for an experimental animal is provided. This management system includes an information identifying unit configured to identify experimental information on the experimental animal to be transported to an experiment site, and a stress value calculating unit configured to calculate a stress value indicating stress to be suffered by the experimental animal during transportation based on the experimental information. The experimental information includes at least a part of a transportation distance for the transportation of the experimental animal, a transportation period for the transportation of the experimental animal, the number of the experimental animals to be transported at a time, an age of the experimental animal, and information on pretreatment given to the experimental animal prior to the transportation.

Abstract: A concentration measurement method performed in a concentration measurement device including an electric unit having a light source and a photodetector, a fluid unit having a measurement cell through which a gas flows, and a processing circuit for calculating a concentration of the gas based on an intensity of a light passing through the measurement cell. The concentration measurement method includes a step of determining an absorption coefficient of the measurement gas using a reference absorption coefficient determined in association with the reference gas and a correction factor associated with the measurement gas, and a step of obtaining a concentration of the measurement gas flowing in the measurement cell using the absorption coefficient of the measurement gas.

Abstract: According to a conventional method for treatment of Sandhoff disease and Tay-Sachs disease comprising administering a modified ?-subunit to a patient in the form of a protein, it is necessary that administration be performed frequently. This invention relates to a recombinant adeno-associated virus virion comprising: capsomere comprising a protein capable of forming a virus virion; and a polynucleotide packaged in the capsomere comprising a promoter sequence and nucleotide sequences operably linked to the promoter sequence encoding a first amino acid sequence derived from the amino acid sequence of the ?-subunit of wild-type human ?-hexosaminidase composed of amino acids 55 to 556 in the sequence as shown in SEQ ID NO: 28 by substitution of amino acids 312 to 318 with glycine, serine, glutamic acid, proline, serine, glycine, and threonine in that order and a second amino acid sequence, which is an amino acid sequence of a signal peptide linked to the N terminus of the first amino acid.

Abstract: An object of the present invention is to provide a method for producing insulin-producing cells having sufficient glucose responsiveness from mesenchymal stem cells, an insulin-producing cell having sufficient glucose responsiveness, a cell structure containing the insulin-producing cell, and a pharmaceutical composition.

Abstract: The laser element includes a gain medium and a photochromic compound that receives a carrier from the gain medium. The gain medium may contain: a first ion including at least one selected from the group consisting of an alkali metal ion, an ammonium ion, a formamidinium ion, a guanidium ion, an imidazolium ion, a pyridinium ion, a pyrrolidinium ion, and a protonated thiourea ion; a second ion including at least one selected from the group consisting of lead, germanium, tin, antimony, and bismuth; and an anion or a ligand including at least one selected from the group consisting of a chloride ion, a bromide ion, an iodide ion, a cyanide ion, a thiocyanate, an isothiocyanate, and a sulfide.

Abstract: The present invention is a heterocycle-containing amino acid compound represented by a general formula (1): wherein R1 and R2 are identical with or different from each other, and each represent a hydrogen atom or a carboxy-protecting group; R3 represents a carboxyl group or a hydroxyl group; and n is 1 or 2, or a salt thereof.

Abstract: A novel tissue usable for a kidney tissue model is provided. A method for producing a kidney-like tissue includes co-culturing a cell group containing mesenchymal stem cells, vascular endothelial cells, and clonal embryonic kidney cells.

Abstract: A lactam compound and a salt thereof, represented by general formulae (1) and (2): In the formulae, R1 and R2 may be the same or different, and each represent a hydrogen atom, a protective group of a carboxyl group or a cation, and X? is a halogen ion, an organic acid ion, or an inorganic acid ion.

Abstract: A concentration measurement method performed in a concentration measurement device including an electric unit having a light source and a photodetector, a fluid unit having a measurement cell through which a gas flows, and a processing circuit for calculating a concentration of the gas based on an intensity of a light passing through the measurement cell. The concentration measurement method includes a step of determining an absorption coefficient of the measurement gas using a reference absorption coefficient determined in association with the reference gas and a correction factor associated with the measurement gas, and a step of obtaining a concentration of the measurement gas flowing in the measurement cell using the absorption coefficient of the measurement gas.

Abstract: The present invention relates to a medical Au-Pt-Pd alloy including Au, Pt,Pd, and inevitable impurities. The Au-Pt-Pd alloy has an alloy compositioninside a polygon (A1-A2-A3-A4) surrounded by straight lines connected at pointA1 (Au: 53 atom%, Pt: 4 atom%, and Pd: 43 atom%), point A2 (Au: 70 atom%,Pt: 4 atom%, and Pd: 26 atom%), point A3 (Au: 69.9 atom%, Pt: 30 atom%, and Pd: 0.1 atom%), and point A4 (Au: 49.9 atom%, Pt: 50 atom%, and Pd: 0.1 atom%) in a Au-Pt-Pd ternary state diagram. In a metal structure of the alloy, at least one of a Au-rich phase and a Pt-rich phase is distributed, and the total of the area ratio of the Au-rich phase and the area ratio of the Pt-rich phase is 1.5% or more and 25.4% or less.

Abstract: The present disclosure addresses the problem of providing at least a composition for suppressing obesity and the problem is solved by a composition for suppressing obesity comprising a prenylflavonoid represented by general formula (1), as an active ingredient, below.

Abstract: The present invention relates to a medical Au—Pt—Pd alloy including Au, Pt, Pd, and inevitable impurities. The alloy has an alloy composition inside a polygon (A1-A2-A3-A4-A5-A6) surrounded by straight lines connected at point A1 (Au: 37.9 atom %, Pt: 0.1 atom %, and Pd: 62 atom %), point A2 (Au: 79.9 atom %, Pt: 0.1 atom %, and Pd: 20 atom %), point A3 (Au: 79.9 atom %, Pt: 20 atom %, and Pd: 0.1 atom %), point A4 (Au: 69.9 atom %, Pt: 30 atom %, and Pd: 0.1 atom %), point A5 (Au: 49 atom %, Pt: 30 atom %, and Pd: 21 atom %), and point A6 (Au: 39 atom %, Pt: 40 atom %, and Pd: 21 atom %) in a Au—Pt—Pd ternary state diagram. The metal structure of the alloy is optimized, and the metal structure is close to a single-phase structure, and has little precipitation of a Au-rich phase and a Pt-rich phase different in composition from a mother phase.

Abstract: An immunosuppressant containing a bispecific molecule including a first binding site that specifically binds to LAG3 and a second binding site that specifically binds to CD3 or CD8.

Abstract: The present invention provides a vinyl alcohol-amino acid ester copolymer that is excellent in properties such as cell culture properties, biocompatibility, antibacterial properties, and solubility in organic solvents, and is applicable to the medical field, the biomaterial field, and the agricultural field (medical and life science fields). Provided is a vinyl alcohol-amino acid ester copolymer including a unit represented by the following formula (1) and a unit represented by the following formula (2): where, in the formula (2), R1 represents a hydrocarbon group that may optionally have a substituent, R2 and R3 each independently represent a hydrogen atom or a hydrocarbon group, and R1 and R2, or R2 and R3, may optionally be bonded together to form a cyclic structure.

Abstract: The present invention relates to a medical Au—Pt—Pd alloy including Au, Pt, Pd, and inevitable impurities. The alloy has an alloy composition inside a polygon (A1-A2-A3-A4-A5-A6) surrounded by straight lines connected at point A1 (Au: 37.9 atom %, Pt: 0.1 atom %, and Pd: 62 atom %), point A2 (Au: 79.9 atom %, Pt: 0.1 atom %, and Pd: 20 atom %), point A3 (Au: 79.9 atom %, Pt: 20 atom %, and Pd: 0.1 atom %), point A4 (Au: 69.9 atom %, Pt: 30 atom %, and Pd: 0.1 atom %), point A5 (Au: 49 atom %, Pt: 30 atom %, and Pd: 21 atom %), and point A6 (Au: 39 atom %, Pt: 40 atom %, and Pd: 21 atom %) in a Au—Pt—Pd ternary state diagram. The metal structure of the alloy is optimized, and the metal structure is close to a single-phase structure, and has little precipitation of a Au-rich phase and a Pt-rich phase different in composition from a mother phase.

Abstract: The present invention provides a vinyl alcohol-vinyl acetate copolymer having excellent solubility and capable of providing a film having high flexibility, high mechanical strength, and high adhesion, and a method for producing a vinyl alcohol-vinyl acetate copolymer. Provided is a vinyl alcohol-vinyl acetate copolymer including a unit of vinyl alcohol and a unit of vinyl acetate, the vinyl alcohol-vinyl acetate copolymer having a triad unit chain ratio TOO of 7.5 or less, where the triad unit chain ratio TOO is obtained using the following formula (1): [ Math .

Abstract: The present invention provides peptides containing the BIG3 polypeptide-binding site in a PHB2 polypeptide, which inhibit the binding between a PHB2 polypeptide and a BIG3 polypeptide, and pharmaceutical compositions containing the peptide. The peptides of the present invention have the ability to bind not to PHB2, whose expression is found in organs throughout the human body, but to BIG3, which is a protein highly expressed specifically in particularly estrogen receptor-positive cancer, and have excellent growth suppressive effects on BIG3-positive cancer cells. Accordingly, the peptides of the present invention are useful as therapeutic agents for breast cancer which can avoid expression of side effects.